HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
h2yN9SBUhh7ruR7w